Familial Hypercholesterolemia (FH) Market Analysis, Market Size, Epidemiology, Leading Companies And Therapies | DelveInsight

May 14 21:06 2021
Familial Hypercholesterolemia (FH) Market Analysis, Market Size, Epidemiology, Leading Companies And Therapies | DelveInsight

DelveInsight Business Research LLP
DelveInsight’s “Familial Hypercholesterolemia (FH) – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Familial Hypercholesterolemia (FH), historical and forecasted epidemiology as well as the Familial Hypercholesterolemia (FH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Familial Hypercholesterolemia (FH) – Market Insights, Epidemiology, and Market Forecast-2030

DelveInsight’s “Familial Hypercholesterolemia (FH) – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the  Familial Hypercholesterolemia (FH), historical and forecasted epidemiology as well as the  Familial Hypercholesterolemia (FH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

  1. A review indicates that Heterozygous FH is much more frequent in comparison with Homozygous FH. As per the estimates provided by this review, the reported prevalence of FH is 1 in 200-1 in 500 for heterozygous state and 1 in 160,000-1 in 1,000, 000 for homozygous state, respectively.

  2. As per a study the estimated overall US prevalence of probable/definite FH was 0.40% (95% confidence interval, 0.32–0.48) or 1 in 250 (95% confidence interval, 1 in 311 to 209). Furthermore, the study had also reported that FH prevalence in the US is varied by age, being least common in 20-29 years old and most common in 60-69 years old.

  3. According to the estimates, the reported prevalence of heterozygous familial hypercholesterolemia in the UK population is estimated to be 1 in 500.

Key benefits of the report:

1. Familial Hypercholesterolemia (FH) market report covers a descriptive overview and comprehensive insight of the Familial Hypercholesterolemia (FH) epidemiology and Familial Hypercholesterolemia (FH) market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. The Familial Hypercholesterolemia (FH) market report provides insights on the current and emerging therapies.

3. Familial Hypercholesterolemia (FH) market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Familial Hypercholesterolemia (FH) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Familial Hypercholesterolemia (FH) market.

Request for sample pages: https://www.delveinsight.com/sample-request/familial-hypercholesterolemia-epidemiology-forecast-report

Familial Hypercholesterolemia (FH): Overview

Familial hypercholesterolemia (FH) is a common life-threatening genetic condition that causes high cholesterol. Untreated, FH leads to early heart attacks and heart disease.People with FH have a high amount of low density lipoprotein (LDL) or “bad cholesterol” due to a mutation in one of the genes that controls the way cholesterol is cleared by the body. As a result, cholesterol accumulates in the bloodstream and can ultimately build up in the walls of the arteries. Cholesterol build up in the artery wall is called hardening of the arteries, or atherosclerosis, and can lead to problems such as heart attacks and strokes in young adults and even children.

The key players involved in Familial Hypercholesterolemia (FH) market:

  1. Genzyme 

  2. Amryt Pharmaceuticals

  3. AstraZeneca

The launch of the emerging therapies is expected to significantly impact the  Familial Hypercholesterolemia (FH) treatment scenario in the upcoming years:-

Drug covered

  1. KYNAMRO

  2. Lojuxta

  3. CRESTOR 

Request a free sample report @https://www.delveinsight.com/sample-request/familial-hypercholesterolemia-epidemiology-forecast-report

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Familial Hypercholesterolemia (FH) Patient Share (%) Overview at a Glance

5. Familial Hypercholesterolemia (FH) Market Overview at a Glance

6. Familial Hypercholesterolemia (FH) Disease Background and Overview

7. Familial Hypercholesterolemia (FH) Epidemiology and Patient Population

8. Country-Specific Patient Population of Familial Hypercholesterolemia (FH)

9. Familial Hypercholesterolemia (FH) Current Treatment and Medical Practices

10. Unmet Needs

11. Familial Hypercholesterolemia (FH) Emerging Therapies

12. Familial Hypercholesterolemia (FH) Market Outlook

13. Country-Wise Familial Hypercholesterolemia (FH) Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Familial Hypercholesterolemia (FH) Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Familial Hypercholesterolemia (FH) – Epidemiology Forecast to 2030

DelveInsight’s ‘Familial Hypercholesterolemia (FH) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Familial Hypercholesterolemia (FH) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/gorakhpurreporter.in/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7